AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06654037
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06616766
Drug: YH42946
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH42946
Trial: NCT06626139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy participants will receive an inactive placebo.
Trial: NCT06696820
Drug: PCSK9 inhibitors combined with atorvastatin/rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single subcutaneous injection of 420 mg Iroceliumab upon admission, along with a standard dose of 20 mg Atorvastatin or 10 mg Rosuvastatin
Trial: NCT06696820
Drug: Atorvastatin/Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Atorvastatin 20 mg / Rosuvastatin 10 mg
Trial: NCT04745689
Drug: AZD2811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions through maintenance phase until PD or other discontinuation criteria.
Trial: NCT06435156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT06685887
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.
Trial: NCT06174909
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
Trial: NCT06795399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-131461 matched placebo will be administered as oral tablets.
Trial: NCT06174909
Drug: Triple Antibiotic paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
Trial: NCT05351671
Drug: RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
Trial: NCT05351671
Drug: Placebo (saline dosed every 8 hours for a total of 3 doses)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
Trial: NCT06619626
Drug: group without alveolar recruitment strategy
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect on mechanical parameters of patients without alveolar recruitment strategy
Trial: NCT04990427
Drug: CLBS201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells
Trial: NCT05173441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
Trial: NCT04837924
Drug: paracetamol 1 gram IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol 1 gram IV every six hours, 4 times in 24 hours
Trial: NCT05555823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching tablets for oral intake
Trial: NCT05555823
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg capsules for oral intake
Trial: NCT05842044
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
Trial: NCT05842044
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
Trial: NCT05842044
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
Trial: NCT04234971
Drug: Intervention group (DBM/BMP)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
Trial: NCT04234971
Drug: Control group(autologous ICBG)
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
Trial: NCT06029439
Drug: NMRA-335140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
Trial: NCT06158841
Drug: Etentamig
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT06474208
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
Trial: NCT06474208
Drug: Formulation 3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.
Trial: NCT06474208
Drug: Formulation 5 (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of formulation 1 in SD.
Trial: NCT06468228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05114278
Drug: oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive an oral iron supplementation (100mg/day).
Trial: NCT05705076
Drug: catheter induced thromboprophylaxis
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulation for catheter induced thromboprophylaxis
Trial: NCT01368315
Drug: CT327 application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
Trial: NCT01368315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
Trial: NCT01368315
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention to one out of four test fields marked on the patient's back.
Trial: NCT05630781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator taken for \~10 days
Trial: NCT05933057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
Trial: NCT05512130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
Trial: NCT05357066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Trial: NCT05168683
Drug: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
Trial: NCT05168683
Drug: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selected dosing of Part One treatments in fasted and/or fed states
Trial: NCT05890534
Drug: Pycnogenol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
Trial: NCT05890534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
Trial: NCT05914688
Drug: LY3209590 (Formulation 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05914688
Drug: LY3209590 (Formulation 2)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04521387
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection in the painful area of humeral epicondyle.
Trial: NCT05459844
Drug: Lutetium[177Lu] Oxodotreotide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Trial: NCT06509503
Drug: Vaginal Ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
Trial: NCT05567770
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
Trial: NCT06158919
Drug: Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable.
Trial: NCT05135130
Drug: ON101 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable in this retrospective study
Trial: NCT05019040
Drug: PA1010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF as control
Trial: NCT05942625
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of matching dose ofplacebo
Trial: NCT04792424
Drug: Vasopressor
RxNorm normalized name: Vasopressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
Trial: NCT04852406
Drug: Protocol-based management of perioperative antithrombotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
Trial: NCT04852406
Drug: Routine management of perioperative antithrombotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antithrombotic therapy is managed according to current routine practice.
Trial: NCT06724432
Drug: oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery
Trial: NCT06724432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
Trial: NCT04642404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug will be a solution with the same taste, texture and color as the drug.
Trial: NCT06323148
Drug: No adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy
Trial: NCT04767191
Drug: artemether lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
Trial: NCT04516993
Drug: The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best treatment arm
Trial: NCT05516979
Drug: 100 mg AP1189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1189 tablets for oral use
Trial: NCT05516979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for oral use
Trial: NCT05076019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Trial: NCT05055583
Drug: Adjuvant treatment stage
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
Trial: NCT05980689
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During neo-CRT: 825mg/m2 bid Monday-Friday per week
Trial: NCT05603403
Drug: Probiatop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 sachet orally, 2 times a day, for 42 days
Trial: NCT05630404
Drug: Surgical ESPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
Trial: NCT05630404
Drug: US guided ESPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
Trial: NCT03637387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT00277693
Drug: Spironolactone (drug)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05594680
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
Trial: NCT05594680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06199440
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
Trial: NCT06199440
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
Trial: NCT06199440
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.
Trial: NCT05478044
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid IV ampoules (20%).
Trial: NCT04807400
Drug: Background lipid lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
Trial: NCT06633185
Drug: phenytoin cream
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: application of the cream after internal anal sphincterotomy versus non application.
Trial: NCT06633185
Drug: no phenytoin cream
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non application of the phenytoin cream
Trial: NCT04875975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period.
Trial: NCT04937816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05876767
Drug: SAR444336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or repeated dose subcutaneous injection